Cargando…

Treatment Options for Cow’s Milk Protein Allergy: A Modeling Analysis

PURPOSE: Cow’s milk protein allergy (CMPA) is one of the most common food allergies in early childhood. We aimed to evaluate clinical and economic outcomes of the amino-acid formula (AAF) and extensively hydrolyzed formula (eHF) based treatment of CMPA by using data available from Turkey and otherwi...

Descripción completa

Detalles Bibliográficos
Autores principales: Berktas, Mehmet, Kirbiyik, Feza, Aribal, Elif, Aksit, Anil, Altintas, Derya Ufuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306455/
https://www.ncbi.nlm.nih.gov/pubmed/32606847
http://dx.doi.org/10.2147/CEOR.S242021
_version_ 1783548655627665408
author Berktas, Mehmet
Kirbiyik, Feza
Aribal, Elif
Aksit, Anil
Altintas, Derya Ufuk
author_facet Berktas, Mehmet
Kirbiyik, Feza
Aribal, Elif
Aksit, Anil
Altintas, Derya Ufuk
author_sort Berktas, Mehmet
collection PubMed
description PURPOSE: Cow’s milk protein allergy (CMPA) is one of the most common food allergies in early childhood. We aimed to evaluate clinical and economic outcomes of the amino-acid formula (AAF) and extensively hydrolyzed formula (eHF) based treatment of CMPA by using data available from Turkey and otherwise from literature. MATERIALS AND METHODS: A theoretical model was developed to evaluate AAF and eHF for CMPA treatment in terms of the number of children tolerating formula or experiencing an allergic reaction or withdrawing formula due to taste or other palatability features and CMPA related direct medical costs from the payer perspective. RESULTS: We estimated that 13,000 children are diagnosed with CMPA in 1 year in Turkey. For the children receiving AAF, it is estimated that 83.7% tolerate AAF until the 24th month, and the total cost for the children tolerating AAF is estimated at 20.6 million€. The average cost per child tolerating AAF until the 24th month is estimated at 1895€. On the other hand, 48.7% are estimated to tolerate eHF until the 24th month, and the total cost for the children tolerating eHF is estimated at 12.3 million€ and the average cost per child tolerating eHF until the 24th month is estimated at 1940€. CONCLUSION: The analysis revealed that the management of CMPA is associated with the economic burden on the healthcare system in Turkey. Treatment of CMPA with AAF seems to provide better clinical outcomes (high tolerability and less withdrawal due to taste or an allergic reaction) and to be an option with economic benefits when Turkey-specific conditions are considered.
format Online
Article
Text
id pubmed-7306455
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-73064552020-06-29 Treatment Options for Cow’s Milk Protein Allergy: A Modeling Analysis Berktas, Mehmet Kirbiyik, Feza Aribal, Elif Aksit, Anil Altintas, Derya Ufuk Clinicoecon Outcomes Res Original Research PURPOSE: Cow’s milk protein allergy (CMPA) is one of the most common food allergies in early childhood. We aimed to evaluate clinical and economic outcomes of the amino-acid formula (AAF) and extensively hydrolyzed formula (eHF) based treatment of CMPA by using data available from Turkey and otherwise from literature. MATERIALS AND METHODS: A theoretical model was developed to evaluate AAF and eHF for CMPA treatment in terms of the number of children tolerating formula or experiencing an allergic reaction or withdrawing formula due to taste or other palatability features and CMPA related direct medical costs from the payer perspective. RESULTS: We estimated that 13,000 children are diagnosed with CMPA in 1 year in Turkey. For the children receiving AAF, it is estimated that 83.7% tolerate AAF until the 24th month, and the total cost for the children tolerating AAF is estimated at 20.6 million€. The average cost per child tolerating AAF until the 24th month is estimated at 1895€. On the other hand, 48.7% are estimated to tolerate eHF until the 24th month, and the total cost for the children tolerating eHF is estimated at 12.3 million€ and the average cost per child tolerating eHF until the 24th month is estimated at 1940€. CONCLUSION: The analysis revealed that the management of CMPA is associated with the economic burden on the healthcare system in Turkey. Treatment of CMPA with AAF seems to provide better clinical outcomes (high tolerability and less withdrawal due to taste or an allergic reaction) and to be an option with economic benefits when Turkey-specific conditions are considered. Dove 2020-06-17 /pmc/articles/PMC7306455/ /pubmed/32606847 http://dx.doi.org/10.2147/CEOR.S242021 Text en © 2020 Berktas et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Berktas, Mehmet
Kirbiyik, Feza
Aribal, Elif
Aksit, Anil
Altintas, Derya Ufuk
Treatment Options for Cow’s Milk Protein Allergy: A Modeling Analysis
title Treatment Options for Cow’s Milk Protein Allergy: A Modeling Analysis
title_full Treatment Options for Cow’s Milk Protein Allergy: A Modeling Analysis
title_fullStr Treatment Options for Cow’s Milk Protein Allergy: A Modeling Analysis
title_full_unstemmed Treatment Options for Cow’s Milk Protein Allergy: A Modeling Analysis
title_short Treatment Options for Cow’s Milk Protein Allergy: A Modeling Analysis
title_sort treatment options for cow’s milk protein allergy: a modeling analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306455/
https://www.ncbi.nlm.nih.gov/pubmed/32606847
http://dx.doi.org/10.2147/CEOR.S242021
work_keys_str_mv AT berktasmehmet treatmentoptionsforcowsmilkproteinallergyamodelinganalysis
AT kirbiyikfeza treatmentoptionsforcowsmilkproteinallergyamodelinganalysis
AT aribalelif treatmentoptionsforcowsmilkproteinallergyamodelinganalysis
AT aksitanil treatmentoptionsforcowsmilkproteinallergyamodelinganalysis
AT altintasderyaufuk treatmentoptionsforcowsmilkproteinallergyamodelinganalysis